Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network

Detalhes bibliográficos
Autor(a) principal: Pinto, Daniel
Data de Publicação: 2019
Outros Autores: Rodrigues, Ana Paula, Nunes, Baltazar
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: http://hdl.handle.net/10400.18/7180
Resumo: Introduction: Type 2 diabetes is a major driver of pharmaceutical spending. We aimed to determine the proportion of new patients who begin treatment with each antidiabetic medicine class, if therapy was initiated by their family physician, if family physicians alter prescriptions initiated by other physicians, and to compare prescribing patterns of family physicians and other specialists. Material and Methods: Cohort-nested cross-sectional study within the Portuguese Sentinel Practice Network. Between 2014 and 2015, incident cases of type 2 diabetes were notified, thus reporting treatment, who made the initial prescription and if treatments initiated by other physicians were changed. Results: A total of 415 incident cases were notified. The initial prescription was made by Sentinel Practice Network physicians in 89.4% of cases (95% CI 86.0% - 92.0%). Metformin was most often chosen as the first treatment, prescribed to 85.5% of patients (95% CI 81.8% – 88.6%). Family physicians used less dipeptidyl peptidase-4 inhibitors (4.2% vs 30.3%, p < 0.001) and insulin (0.3% vs 12.1%, p < 0.001) compared to other specialists. Prescriptions initiated by others were changed in 4.5% of cases (95% CI 0.4% - 16.0%). Discussion: Prospective data collection is a major study strength, but few cases of treatment initiated by non-family physicians were notified. Data for disease severity was unavailable and could partly explain differences between family physicians and other specialists. Conclusion: Metformin was most often chosen as initial therapy, in line with Portuguese guideline recommendations. Sentinel Practice Network physicians diagnosed most cases, seldom changed prescriptions initiated by others, and had a different pattern of antidiabetic medicines use compared to other specialists.
id RCAP_889e3935b89c4d26ad1320c123b1476e
oai_identifier_str oai:repositorio.insa.pt:10400.18/7180
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice NetworkEscolhas Terapêuticas Iniciais para a Diabetes Tipo 2 na Rede de Médicos SentinelaDiabetes MellitusDiabetes Mellitus, Type 2Cross-Sectional StudiesDipeptidyl-Peptidase IV InhibitorsDisease NotificationFamily PracticeFemaleHumansHypoglycemic AgentsInsulinLife StyleMaleMetforminMiddle AgedAgedPractice Patterns, Physicians'Diabetes Mellitus Tiye 2/Drug TherapyPrimary Health CareSentinel SurveillancePortugalDiabetes Mellitus Tipe 2/tratamentoHipoglicemiantesCuidados de SaúdeCuidados de Saúde PrimáriosVigilância de Evento SentinelaMédicos-sentinelaIntroduction: Type 2 diabetes is a major driver of pharmaceutical spending. We aimed to determine the proportion of new patients who begin treatment with each antidiabetic medicine class, if therapy was initiated by their family physician, if family physicians alter prescriptions initiated by other physicians, and to compare prescribing patterns of family physicians and other specialists. Material and Methods: Cohort-nested cross-sectional study within the Portuguese Sentinel Practice Network. Between 2014 and 2015, incident cases of type 2 diabetes were notified, thus reporting treatment, who made the initial prescription and if treatments initiated by other physicians were changed. Results: A total of 415 incident cases were notified. The initial prescription was made by Sentinel Practice Network physicians in 89.4% of cases (95% CI 86.0% - 92.0%). Metformin was most often chosen as the first treatment, prescribed to 85.5% of patients (95% CI 81.8% – 88.6%). Family physicians used less dipeptidyl peptidase-4 inhibitors (4.2% vs 30.3%, p < 0.001) and insulin (0.3% vs 12.1%, p < 0.001) compared to other specialists. Prescriptions initiated by others were changed in 4.5% of cases (95% CI 0.4% - 16.0%). Discussion: Prospective data collection is a major study strength, but few cases of treatment initiated by non-family physicians were notified. Data for disease severity was unavailable and could partly explain differences between family physicians and other specialists. Conclusion: Metformin was most often chosen as initial therapy, in line with Portuguese guideline recommendations. Sentinel Practice Network physicians diagnosed most cases, seldom changed prescriptions initiated by others, and had a different pattern of antidiabetic medicines use compared to other specialists.Introdução: A diabetes tipo 2 tem um peso significativo nas despesas com medicamentos. Determinámos a proporção de novos doentes que iniciaram tratamento com cada classe de antidiabéticos, se o tratamento foi iniciado pelos médicos de família, se estes alteram as prescrições de outros médicos e comparámos padrões de prescrição de médicos de família e outros especialistas. Material e Métodos: Estudo transversal aninhado em coorte na Rede de Médicos Sentinela. Entre 2014 e 2015 casos incidentes de diabetes tipo 2 foram notificados, reportando o tratamento, quem fez a prescrição inicial e se tratamentos iniciados por outros médicos foram alterados. Resultados: Foram notificados 415 casos incidentes. Os Médicos Sentinela fizeram a prescrição inicial em 89,4% dos casos (IC 95% 86,0% - 92,0%). O tratamento inicial mais escolhido foi a metformina, em 85,5% dos doentes (IC 95% 81,8% - 88,6%). Os médicos de família utilizaram menos inibidores da dipeptidil peptidase-4 (4,2% vs 30,3%, p < 0,001) e insulina (0,3% vs 12,1%, p < 0,001) que outros especialistas. As prescrições iniciadas por outros foram alteradas em 4,5% dos casos (IC 95% 0,4% - 16,0%). Discussão: A colheita prospectiva dos dados é um ponto forte, mas foram notificados poucos casos de tratamento iniciado por outros especialistas. Dados sobre a gravidade da doença não estavam disponíveis e podem explicar parte das diferenças entre médicos de família e outros especialistas. Conclusão: A metformina foi o tratamento inicial mais escolhido, em linha com as recomendações das normas de orientação clínica Portuguesas. Os médicos da Rede Sentinela diagnosticaram a maioria dos casos, raramente alteraram prescrições iniciadas por outros e tiveram um padrão de prescrição diferente de outros especialistas.Ordem dos MédicosRepositório Científico do Instituto Nacional de SaúdePinto, DanielRodrigues, Ana PaulaNunes, Baltazar2020-08-03T13:57:28Z2019-052019-05-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.18/7180engActa Med Port 2019 May;32(5):375-380. doi:10.20344/amp.104141646-075810.20344/amp.10414info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-07-20T15:41:50Zoai:repositorio.insa.pt:10400.18/7180Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T18:41:50.153776Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
Escolhas Terapêuticas Iniciais para a Diabetes Tipo 2 na Rede de Médicos Sentinela
title Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
spellingShingle Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
Pinto, Daniel
Diabetes Mellitus
Diabetes Mellitus, Type 2
Cross-Sectional Studies
Dipeptidyl-Peptidase IV Inhibitors
Disease Notification
Family Practice
Female
Humans
Hypoglycemic Agents
Insulin
Life Style
Male
Metformin
Middle Aged
Aged
Practice Patterns, Physicians'
Diabetes Mellitus Tiye 2/Drug Therapy
Primary Health Care
Sentinel Surveillance
Portugal
Diabetes Mellitus Tipe 2/tratamento
Hipoglicemiantes
Cuidados de Saúde
Cuidados de Saúde Primários
Vigilância de Evento Sentinela
Médicos-sentinela
title_short Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
title_full Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
title_fullStr Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
title_full_unstemmed Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
title_sort Initial Therapeutic Choices for Type 2 Diabetes in the Portuguese Sentinel Practice Network
author Pinto, Daniel
author_facet Pinto, Daniel
Rodrigues, Ana Paula
Nunes, Baltazar
author_role author
author2 Rodrigues, Ana Paula
Nunes, Baltazar
author2_role author
author
dc.contributor.none.fl_str_mv Repositório Científico do Instituto Nacional de Saúde
dc.contributor.author.fl_str_mv Pinto, Daniel
Rodrigues, Ana Paula
Nunes, Baltazar
dc.subject.por.fl_str_mv Diabetes Mellitus
Diabetes Mellitus, Type 2
Cross-Sectional Studies
Dipeptidyl-Peptidase IV Inhibitors
Disease Notification
Family Practice
Female
Humans
Hypoglycemic Agents
Insulin
Life Style
Male
Metformin
Middle Aged
Aged
Practice Patterns, Physicians'
Diabetes Mellitus Tiye 2/Drug Therapy
Primary Health Care
Sentinel Surveillance
Portugal
Diabetes Mellitus Tipe 2/tratamento
Hipoglicemiantes
Cuidados de Saúde
Cuidados de Saúde Primários
Vigilância de Evento Sentinela
Médicos-sentinela
topic Diabetes Mellitus
Diabetes Mellitus, Type 2
Cross-Sectional Studies
Dipeptidyl-Peptidase IV Inhibitors
Disease Notification
Family Practice
Female
Humans
Hypoglycemic Agents
Insulin
Life Style
Male
Metformin
Middle Aged
Aged
Practice Patterns, Physicians'
Diabetes Mellitus Tiye 2/Drug Therapy
Primary Health Care
Sentinel Surveillance
Portugal
Diabetes Mellitus Tipe 2/tratamento
Hipoglicemiantes
Cuidados de Saúde
Cuidados de Saúde Primários
Vigilância de Evento Sentinela
Médicos-sentinela
description Introduction: Type 2 diabetes is a major driver of pharmaceutical spending. We aimed to determine the proportion of new patients who begin treatment with each antidiabetic medicine class, if therapy was initiated by their family physician, if family physicians alter prescriptions initiated by other physicians, and to compare prescribing patterns of family physicians and other specialists. Material and Methods: Cohort-nested cross-sectional study within the Portuguese Sentinel Practice Network. Between 2014 and 2015, incident cases of type 2 diabetes were notified, thus reporting treatment, who made the initial prescription and if treatments initiated by other physicians were changed. Results: A total of 415 incident cases were notified. The initial prescription was made by Sentinel Practice Network physicians in 89.4% of cases (95% CI 86.0% - 92.0%). Metformin was most often chosen as the first treatment, prescribed to 85.5% of patients (95% CI 81.8% – 88.6%). Family physicians used less dipeptidyl peptidase-4 inhibitors (4.2% vs 30.3%, p < 0.001) and insulin (0.3% vs 12.1%, p < 0.001) compared to other specialists. Prescriptions initiated by others were changed in 4.5% of cases (95% CI 0.4% - 16.0%). Discussion: Prospective data collection is a major study strength, but few cases of treatment initiated by non-family physicians were notified. Data for disease severity was unavailable and could partly explain differences between family physicians and other specialists. Conclusion: Metformin was most often chosen as initial therapy, in line with Portuguese guideline recommendations. Sentinel Practice Network physicians diagnosed most cases, seldom changed prescriptions initiated by others, and had a different pattern of antidiabetic medicines use compared to other specialists.
publishDate 2019
dc.date.none.fl_str_mv 2019-05
2019-05-01T00:00:00Z
2020-08-03T13:57:28Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/10400.18/7180
url http://hdl.handle.net/10400.18/7180
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Acta Med Port 2019 May;32(5):375-380. doi:10.20344/amp.10414
1646-0758
10.20344/amp.10414
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Ordem dos Médicos
publisher.none.fl_str_mv Ordem dos Médicos
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799132162787639296